title: Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
abstract: A randomized, controlled clinical trial was conducted to compare the use of epirubicin (EPI) and doxorubicin (DOX) in Lipiodol (Laboratoire Guerbet, Roissy-Charles-de-Gaulle Cedex, France)-transcatheter arterial chemoembolization as a treatment of hepatocellular carcinoma. One hundred ninety-two hospitals participated, and 415 patients were enrolled in the study during the period between October 1989 and December 1990. The patients were randomly allocated to group A (EPI) or group B (DOX) by a centralized telephone registration. The actual doses of EPI and DOX were 72 mg/body and 48 mg/body, respectively. The 1-, 2-, and 3-year survival rates were, respectively, 69%, 44%, and 33% for group A and 73%, 54%, and 37% for group B. There were no statistically significant differences (P = .2296, log-rank test). When each group of patients was classified retrospectively into high-risk and low-risk subgroups based on the severity index calculated by the Cox regression model from the significant prognostic factors (the pretreatment tumor size, the pretreatment serum alpha-fetoprotein level, tumor encroachment, and Child's classification), the survival curve of the low-risk DOX subgroup was significantly superior to that of the low-risk EPI subgroup (P = .0182). However, there was no significant difference between the high-risk subgroups (P = .4606). The change in the serum alpha-fetoprotein level, the extent of Lipiodol accumulation in the tumor, and the extent of tumor reduction after the treatment did not show any significant differences between the groups. The white blood cell count in group B showed a tendency to decrease slightly more than in group A at 3 weeks after Lipiodol-transcatheter arterial chemoembolization. In conclusion, there was no statistically significant difference between the survival curves of the EPI and DOX groups in Lipiodol-transcatheter arterial embolization treatment of hepatocellular carcinoma.
authors.affiliation: Department of Surgery, International Medical Center of Japan, Tokyo.
authors.forename: S
authors.initials: S
authors.lastname: Kawai
authors.forename: M
authors.initials: M
authors.lastname: Tani
authors.forename: J
authors.initials: J
authors.lastname: Okamura
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: M
authors.initials: M
authors.lastname: Monden
authors.forename: S
authors.initials: S
authors.lastname: Hayashi
authors.forename: J
authors.initials: J
authors.lastname: Inoue
authors.forename: Y
authors.initials: Y
authors.lastname: Kawarada
authors.forename: M
authors.initials: M
authors.lastname: Kusano
authors.forename: Y
authors.initials: Y
authors.lastname: Kubo
authors.forename: C
authors.initials: C
authors.lastname: Kuroda
authors.forename: Y
authors.initials: Y
authors.lastname: Sakata
authors.forename: Y
authors.initials: Y
authors.lastname: Shimamura
authors.forename: K
authors.initials: K
authors.lastname: Jinno
authors.forename: A
authors.initials: A
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Takayasu
authors.forename: K
authors.initials: K
authors.lastname: Tamura
authors.forename: N
authors.initials: N
authors.lastname: Nagasue
authors.forename: Y
authors.initials: Y
authors.lastname: Nakanishi
authors.forename: M
authors.initials: M
authors.lastname: Makino
authors.forename: M
authors.initials: M
authors.lastname: Masuzawa
authors.forename: Y
authors.initials: Y
authors.lastname: Yumoto
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: T
authors.initials: T
authors.lastname: Oda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000903:Antibiotics, Antineoplastic; D000509:alpha-Fetoproteins; D015251:Epirubicin; D007459:Iodized Oil; D004317:Doxorubicin